Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# Avenzo Therapeutics

Developing the next generation of oncology therapies for patients.

## Sitemaps

- [XML Sitemap](https://avenzotx.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Avenzo Therapeutics Announces Appointment of Barbara Bodem and  Elizabeth Mily to Board of Directors as Independent Directors](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-appointment-of-barbara-bodem-and-elizabeth-mily-to-board-of-directors-as-independent-directors/)
- [Avenzo Therapeutics to Participate in the Upcoming Wells Fargo 21st Annual Healthcare Conference](https://avenzotx.com/press-releases/avenzo-therapeutics-to-participate-in-the-upcoming-wells-fargo-21st-annual-healthcare-conference/)
- [Wells Fargo 21st Annual Healthcare Conference](https://avenzotx.com/2026/wells-fargo-21st-annual-healthcare-conference/)
- [Avenzo Therapeutics Announces Appointment of Connie Wedel  as Chief Human Resources Officer](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-appointment-of-connie-wedel-as-chief-human-resources-officer/)
- [Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement](https://avenzotx.com/press-releases/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement/)
- [Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting](https://avenzotx.com/press-releases/avenzo-therapeutics-presents-updated-results-from-the-phase-1-2-study-of-avzo-021-a-potentially-differentiated-cdk2-inhibitor-at-the-2026-american-society-of-clinical-oncology-annual-meeting/)
- [Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-first-patient-dosed-in-combination-cohort-evaluating-cdk4-selective-inhibitor-avzo-023-with-cdk2-selective-inhibitor-avzo-021-in-ongoing-phase-1-2-orion-1-study/)
- [Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing  Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer](https://avenzotx.com/press-releases/avenzo-therapeutics-advances-the-combination-of-cdk4-selective-inhibitor-avzo-023-with-cdk2-selective-inhibitor-avzo-021-in-ongoing-phase-1-orion-1-study-in-hr-her2-breast-cancer/)
- [Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of  AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting](https://avenzotx.com/press-releases/avenzo-therapeutics-to-present-updated-results-from-the-phase-1-study-of-avzo-021-a-potential-best-in-class-cdk2-inhibitor-at-the-2026-american-society-of-clinical-oncology-annual-meeting/)
- [Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of  AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium](https://avenzotx.com/press-releases/avenzo-therapeutics-presents-initial-results-from-the-phase-1-2-study-of-avzo-021-a-potential-best-in-class-cdk2-inhibitor-at-the-2025-san-antonio-breast-cancer-symposium/)
- [Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin](https://avenzotx.com/press-releases/avenzo-therapeutics-granted-fast-track-designation-for-avzo-103-a-potential-best-in-class-nectin4-trop2-bispecific-antibody-drug-conjugate-for-the-treatment-of-patients-with-urothelial-cancer-previo/) - Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (BsADC).
- [Avenzo Therapeutics Announces Appointment of  Scott Lipman as Chief Financial Officer](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-appointment-of-scott-lipman-as-chief-financial-officer/)
- [Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC](https://avenzotx.com/press-releases/avenzo-therapeutics-granted-fast-track-designation-for-avzo-1418-a-potential-best-in-class-egfr-her3-bispecific-adc-for-the-treatment-of-patients-with-egfr-mutated-tki-pretreated-nsclc/)
- [Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of  AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the  2025 San Antonio Breast Cancer Symposium](https://avenzotx.com/press-releases/avenzo-therapeutics-to-present-initial-results-from-the-phase-1-study-of-avzo-021-a-potential-best-in-class-cdk2-inhibitor-at-the-2025-san-antonio-breast-cancer-symposium/)
- [Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate](https://avenzotx.com/press-releases/avenzo-therapeutics-initiates-phase-1-2-clinical-study-of-avzo-103-a-potential-best-in-class-nectin4-trop2-bispecific-antibody-drug-conjugate/)
- [Avenzo Therapeutics Announces $60 Million Series B Financing](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-60-million-series-b-financing/)
- [Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-avzo-103-a-potential-best-in-class-nectin4-trop2-bispecific-antibody-drug-conjugate/)
- [Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-study-of-avzo-1418-a-potential-best-in-class-egfr-her3-bispecific-antibody-drug-conjugate/)
- [Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor](https://avenzotx.com/press-releases/avenzo-therapeutics-initiates-phase-1-2-clinical-study-of-avzo-023-a-potential-best-in-class-novel-cdk4-selective-inhibitor/)
- [Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate](https://avenzotx.com/press-releases/avenzo-therapeutics-initiates-phase-1-2-clinical-study-of-avzo-1418-a-potential-best-in-class-novel-egfr-her3-bispecific-antibody-drug-conjugate/)
- [Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-avzo-1418-a-potential-best-in-class-novel-egfr-her3-bispecific-antibody-drug-conjugate/)
- [Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-avzo-023-arts-023-a-potential-best-in-class-novel-cdk4-selective-inhibitor/)
- [Exclusive: Athena Countouriotis' Avenzo taps Shanghai biotech for ADC, adds new funds](https://avenzotx.com/article/exclusive-athena-countouriotis-avenzo-taps-shanghai-biotech-for-adc-adds-new-funds/)
- [Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBio](https://avenzotx.com/article/exclusive-avenzo-picks-up-another-adc-this-time-with-multi-partnered-dualitybio/)
- [Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate](https://avenzotx.com/press-releases/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate/) - Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 antibody-drug conjugate
- [Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-appointment-of-patrick-machado-j-d-to-board-of-directors-as-independent-director/) - Avenzo Therapeutics, Inc. today announced that Goldman Sachs is recognizing Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo, as one of the Most Exceptional Entrepreneurs of 2024 at its Builders and Innovators Summit
- [Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing](https://avenzotx.com/press-releases/avenzo-therapeutics-provides-corporate-update-and-announces-closing-of-series-a-a-1-financing/) - Avenzo Therapeutics, Inc. today announced that Goldman Sachs is recognizing Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo, as one of the Most Exceptional Entrepreneurs of 2024 at its Builders and Innovators Summit
- [Avenzo Therapeutics Honored by Goldman Sachs for Entrepreneurship](https://avenzotx.com/press-releases/avenzo-therapeutics-honored-by-goldman-sachs-for-entrepreneurship/) - Avenzo Therapeutics, Inc. today announced that Goldman Sachs is recognizing Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo, as one of the Most Exceptional Entrepreneurs of 2024 at its Builders and Innovators Summit
- [Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-appointment-of-garry-nicholson-to-board-of-directors-as-independent-director/)
- [Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-avzo-021-and-trodelvy-in-hr-her2-metastatic-breast-cancer/)
- [For Chinese biotechs, the out-licensing business is scorching hot. Could geopolitics rain on their parade?](https://avenzotx.com/article/for-chinese-biotechs-the-out-licensing-business-is-scorching-hot-could-geopolitics-rain-on-their-parade/)
- [Exclusive: Athena Countouriotis' Avenzo nabs $150M to in-license more assets](https://avenzotx.com/article/exclusive-athena-countouriotis-avenzo-nabs-150m-to-in-license-more-assets/)
- [Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-150-million-oversubscribed-financing-to-advance-emerging-oncology-pipeline/)
- [Exclusive: After Turning Point success, oncology vets in-license first asset for Avenzo Therapeutics](https://avenzotx.com/article/exclusive-after-turning-point-success-oncology-vets-in-license-first-asset-for-avenzo-therapeutics/)
- [Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics](https://avenzotx.com/press-releases/avenzo-therapeutics-announces-global-license-of-avzo-021-arts-021-a-potentially-best-in-class-clinical-stage-cdk2-inhibitor-from-allorion-therapeutics/)
- [How biotech deal-making really works behind the scenes, according to founders](https://avenzotx.com/article/how-biotech-deal-making-really-works-behind-the-scenes-according-to-founders/)
- [NASDAQ: In Conversation With Avenzo](https://avenzotx.com/video/nasdaq-in-conversation-with-avenzo/)
- [Turning Point team quietly reforms at Avenzo, raises $196M](https://avenzotx.com/article/turning-point-team-quietly-reforms-at-avenzo-raises-196m/)
- [Ex-Turning Point execs plan to have their next bet, Avenzo, on the Nasdaq next summer](https://avenzotx.com/article/ex-turning-point-execs-plan-to-have-their-next-bet-avenzo-on-the-nasdaq-next-summer/)
- [Handful of biotechs expected to IPO this fall, but many are stuck in ‘holding pattern’ until 2024](https://avenzotx.com/article/handful-of-biotechs-expected-to-ipo-this-fall-but-many-are-stuck-in-holding-pattern-until-2024/)

## Pages

- [Home](https://avenzotx.com/) - Developing the next generation of oncology therapies for patients.
- [About Us](https://avenzotx.com/about-us/) - Avenzo Therapeutics
- [Careers](https://avenzotx.com/careers/)
- [Pipeline & Science](https://avenzotx.com/pipeline-and-science/)
- [News](https://avenzotx.com/news/)
- [Privacy Policy](https://avenzotx.com/privacy-policy/)
- [Terms of Service](https://avenzotx.com/terms-of-service/)

## Portfolio Items

- [Elizabeth A. Mily](https://avenzotx.com/team/elizabeth-mily/)
- [Barbara Bodem](https://avenzotx.com/team/barbara-bodem/)
- [Garry Nicholson, M.B.A.](https://avenzotx.com/team/garry-nicholson/)
- [Heather Sun](https://avenzotx.com/team/ryan-bloomer-2/)
- [Connie Wedel](https://avenzotx.com/team/connie-wedel/)
- [Brian Sun, J.D.](https://avenzotx.com/team/brian-sun/)
- [Athena Countouriotis, M.D.](https://avenzotx.com/team/athena-countouriotis/)
- [Ryan Bloomer](https://avenzotx.com/team/ryan-bloomer/)
- [Homa Yeganegi](https://avenzotx.com/team/homa-yeganegi/)
- [Patrick Machado, J.D.](https://avenzotx.com/team/patrick-machado-j-d/)
- [Carl Gordon, Ph.D., C.F.A.](https://avenzotx.com/team/carl-gordon/)
- [Simeon George, M.D.](https://avenzotx.com/team/simeon-george/)
- [Jakob Dupont, M.D., M.A.](https://avenzotx.com/team/jakob-dupont-md-ma/)
- [Athena Countouriotis, M.D.](https://avenzotx.com/team/athena-countouriotis-board/)
- [Mohammad Hirmand, M.D.](https://avenzotx.com/team/mohammad-hirmand/)

## Categories

- [Press Releases](https://avenzotx.com/category/press-releases/)
- [Video](https://avenzotx.com/category/video/)
- [Article](https://avenzotx.com/category/article/)
- [Avenzo in the News](https://avenzotx.com/category/avenzo-in-the-news/)
- [2024](https://avenzotx.com/category/2024/)
- [2023](https://avenzotx.com/category/2023/)
- [2025](https://avenzotx.com/category/2025/)
- [2026](https://avenzotx.com/category/2026/)
- [Events & Presentations](https://avenzotx.com/category/events-presentations/)

## Tags

- [Event](https://avenzotx.com/tag/event/)

## Portfolio Categories

- [leadership](https://avenzotx.com/team/leadership/)
- [directors](https://avenzotx.com/team/directors/)